Literature DB >> 284710

The effect of suppressive therapy of nontoxic diffuse goiter on serum levels of thyroxine, 3,5,3'-triiodothyronine and 3,3',5'-triiodothyronine.

K Johansen, J M Hansen, H Perrild, L Skovsted, J P Kampmann.   

Abstract

We studied the effect of suppressive therapy with graded doses of thyroxine (T4) on serum levels of T4, 3,5,3'-triiodothyronine (T3) and 3,3',5'-triiodothyronine [rT3] in patients with diffuse, nontoxic goiter. For comparison and in order to elucidate the degree of suppression of the pituitary thyroid axis by T3 the effect of suppressive therapy with T3 was studied in the same type of patients. We found that T4 in serum rose significantly to a constant level during T4 treatment (0.10, 0.15 and 0.20 mg/day). Dose-related rises in T4 were only seen after 3 months of treatment. T3 and rT3 only changed minimally. The T4/T3 ratio rose to a constant level during the initial 3 months of treatment. T3/rT3 ratio remained unchanged. No dose-related differences in T4/T3 and T3/rT3 ratio were observed. Treatment with T3 in doses of 0.06 mg per day caused a significant but slow fall in T4 and rT3 to hypothroid levels while T3 only rose slightly. The T4/T3 ratio dropped significantly during T3 therapy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 284710     DOI: 10.1111/j.0954-6820.1979.tb00714.x

Source DB:  PubMed          Journal:  Acta Med Scand Suppl        ISSN: 0365-463X


  3 in total

1.  Beta 2-adrenoceptor agonists and thyroid hormones.

Authors:  J P Kampmann; T L Svendsen; L Skovsted; J E Mølholm Hansen
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

2.  Elevated serum thyroxine concentration in patients receiving "replacement" doses of levothyroxine.

Authors:  J C Ingbar; M Borges; S Iflah; R E Kleinmann; L E Braverman; S H Ingbar
Journal:  J Endocrinol Invest       Date:  1982 Mar-Apr       Impact factor: 4.256

3.  Thyroxine uptake by human hepatoma cells from serum of patients submitted to long-term thyroxine suppressive therapy.

Authors:  L Bartalena; E Martino; M Falcone; A Pacchiarotti; A Pinchera
Journal:  J Endocrinol Invest       Date:  1988-10       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.